Atara Biotherapeutics, Inc. ATRA
We take great care to ensure that the data presented and summarized in this overview for Atara Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATRA
View all-
Eco R1 Capital, LLC San Francisco, CA10.2MShares$3.97 Million0.2% of portfolio
-
Redmile Group, LLC San Francisco, CA9.26MShares$3.61 Million0.25% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$2.66 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC6.58MShares$2.57 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.51MShares$2.54 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$1.96 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.96MShares$1.93 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.15MShares$1.62 Million0.15% of portfolio
-
Vestal Point Capital, LP New York, NY2.8MShares$1.09 Million0.16% of portfolio
-
Acadian Asset Management LLC Boston, MA2.64MShares$1.03 Million0.01% of portfolio
Latest Institutional Activity in ATRA
Top Purchases
Top Sells
About ATRA
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Transactions at ATRA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
Pascal Touchon President and CEO |
SELL
Open market or private sale
|
Direct |
81,506
-4.27%
|
$0
$0.62 P/Share
|
May 16
2024
|
Jill Henrich EVP, Global Head RA & Quality |
SELL
Open market or private sale
|
Direct |
25,750
-4.64%
|
$0
$0.62 P/Share
|
May 16
2024
|
Eric J Hyllengren EVP, CFO |
SELL
Open market or private sale
|
Direct |
28,648
-4.25%
|
$0
$0.62 P/Share
|
May 16
2024
|
Amar Murugan EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
32,401
-4.45%
|
$0
$0.62 P/Share
|
May 16
2024
|
Anh Co Nguyen EVP, Chief Sci. & Tech Officer |
SELL
Open market or private sale
|
Direct |
42,899
-4.56%
|
$0
$0.62 P/Share
|
Mar 31
2024
|
Ameet Mallik |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+39.74%
|
-
|
Mar 31
2024
|
Carol Giltner Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+19.24%
|
-
|
Mar 31
2024
|
Maria Grazia Roncarolo |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+38.61%
|
-
|
Mar 31
2024
|
William K Heiden |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+29.47%
|
-
|
Mar 31
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+36.67%
|
-
|
Mar 04
2024
|
Amar Murugan EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,044
-1.36%
|
$0
$0.72 P/Share
|
Mar 04
2024
|
Anh Co Nguyen EVP, Chief Sci. & Tech Officer |
SELL
Open market or private sale
|
Direct |
10,746
-1.13%
|
$0
$0.72 P/Share
|
Mar 04
2024
|
Pascal Touchon President and CEO |
SELL
Open market or private sale
|
Direct |
24,844
-1.28%
|
$0
$0.72 P/Share
|
Mar 04
2024
|
Jill Henrich EVP, Global Head RA & Quality |
SELL
Open market or private sale
|
Direct |
3,879
-0.69%
|
$0
$0.72 P/Share
|
Mar 04
2024
|
Eric J Hyllengren EVP, CFO |
SELL
Open market or private sale
|
Direct |
6,679
-0.49%
|
$0
$0.72 P/Share
|
Jan 08
2024
|
Jill Henrich EVP, Global Head RA & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
450,000
+44.6%
|
-
|
Jan 08
2024
|
Eric J Hyllengren EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
475,000
+41.09%
|
-
|
Jan 08
2024
|
Amar Murugan EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
475,000
+39.17%
|
-
|
Jan 08
2024
|
Anh Co Nguyen EVP, Chief Sci. & Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
675,000
+41.48%
|
-
|
Jan 08
2024
|
Pascal Touchon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,280,000
+39.81%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 4.11M shares |
---|---|
Open market or private purchase | 817K shares |
Open market or private sale | 420K shares |
---|